Skip to content
Review Open access

POTENTIAL USE OF GLP-1 RECEPTOR AGONISTS IN THE MANAGEMENT OF CHRONIC PAIN SYNDROMES: ANTI-INFLAMMATORY AND NEUROPROTECTIVE PERSPECTIVES

Sep 2026 · International Journal of Innovative Technologies in Social Science · 0 citations · 18 references

Abstract

Chronic pain syndromes remain a major clinical and public health challenge because of their multifactorial pathophysiology, frequent refractoriness to standard treatment, and marked effects on quality of life, disability, sleep, psychological well-being, and work capacity. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), initially developed for type 2 diabetes and obesity, have recently attracted growing interest beyond metabolic medicine because their biological actions appear to extend to anti-inflammatory, antioxidative, neuroprotective, and cytoprotective pathways. These pleiotropic properties are potentially relevant to chronic pain, which is increasingly understood as a condition sustained not only by nociceptive input but also by neuroinflammation, glial activation, oxidative stress, maladaptive neuronal plasticity, mitochondrial dysfunction, and metabolic dysregulation. This narrative review examines the current biological and translational rationale for GLP-1RAs in chronic pain syndromes, with emphasis on neuropathic pain, diabetic peripheral neuropathy, migraine-related central sensitization, fibromyalgia-related mechanisms, osteoarthritis-associated pain, inflammatory musculoskeletal pain, and visceral pain. Available evidence suggests that GLP-1 receptor activation may modulate several processes implicated in pain chronification, including pro-inflammatory cytokine signaling, microglial activation, oxidative stress, mitochondrial dysfunction, and impaired neuronal resilience. Experimental studies also indicate possible involvement of IL-10-mediated anti-inflammatory signaling, AMPK/NF-kappaB pathway modulation, and broader neuroimmune regulation. However, the current evidence base remains heterogeneous and is still dominated by preclinical studies, mechanistic reviews, and early observational data. Human evidence in non-diabetic chronic pain populations remains limited, and in many settings it is difficult to separate direct analgesic effects from indirect benefits related to weight loss, improved glycemic control, reduced systemic inflammation, or improved function. At present, GLP-1RAs should therefore be regarded as biologically plausible and clinically promising, but still investigational, candidates in chronic pain management rather than established analgesic therapies. Further translational work and adequately powered prospective clinical studies are required to clarify efficacy, safety, mechanism-specific effects, and phenotype-specific patient selection.

Read PDF

Similar papers

Review Open access Oct 2026

Modulating neuroinflammation with glucagon-like peptide-1 receptor agonists: a scoping review exploring their therapeutic potential in schizophrenia.

Neuroinflammation is a key contributor to the pathophysiology and symptomatology of schizophrenia spectrum disorders. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), clinically approved anti-diabetic and -obesity medication, have been associated with anti-inflammatory properties. It remains unclear whether GLP-1R...

Barbara J. Otto, Jasper B. Zantvoord, D. Siskind et al. · 0 citations
Open access Oct 2026

Peripheral neuropathy in patients using GLP-1 receptor agonists: emerging clinical concerns

Background: Glucagon-like peptide-1 receptor agonists have become widely used in the management of diabetes mellitus and obesity due to their efficacy in glycemic control and weight reduction. Although generally considered safe, the rapid metabolic and weight changes associated with these agents have raised questions r...

Victoria Ferrari Machado, Mariah Favarato Menegatti, Vithória Nicolini Libardi et al. · 0 citations
Review Open access Oct 2026

Targeting Key Mechanisms of Nutraceuticals in Chronic Pain: A Narrative Review.

A mechanism-based overview of nutraceuticals in CP across five interconnected domains is provided: neuroinflammation, oxidative stress and mitochondrial dysfunction, central sensitization, peripheral sensitization, peripheral sensitization, and descending inhibitory modulation.

V. Schweiger, Barbara Ganz, E. Secchettin et al. · 0 citations
Review Open access Sep 2026

Emerging pharmacological strategies for neuropathic pain: Mechanism-based targeting and precision medicine

Neuropathic pain (NP) is a type of chronic pain syndrome due to structural or functional alterations in the somatosensory nervous system after injury, including long-lasting painful sensations and allodynia and hyperalgesia. Due to its intricate pathophysiology and significant interindividual variation in therapeutic r...

Rui Zhao · 0 citations
Review Open access Oct 2026

GLP-1 Receptor Agonists as Multisystem Therapeutics: Mechanistic Basis, Translational Evidence, and Emerging Clinical Applications Beyond Metabolic Disease

Overall, GLP-1-based therapies represent a promising platform for addressing interconnected metabolic and non-metabolic diseases, however, the strength of evidence varies substantially across indications, highlighting the need for well-designed clinical trials, long-term safety evaluation, and clearer identification of...

Preeti Sah, Z. Husain, Kashish Verma Verma et al. · 0 citations
Review Open access Sep 2026

Neuroprotective Potential of GLP-1 Receptor Agonists in Neurodegenerative Diseases: Narrative Review

GLP-1 RAs demonstrate promising neuroprotective properties in preclinical and observational studies, though a clinical dualism exists where motor benefits in PD appear highly dependent on formulation kinetics.

Paulina Orzechowska, Gabriela Budziszewska, Aneta Dziurdź et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.